Hydrocodone (HC) is a highly misused prescription drugs in the USA. Interpretation of urine tests for HC is complicated by its metabolism to two metabolites, hydromorphone (HM) and dihydrocodeine (DHC), which are also available commercially and are misused. Currently, there is interest in including HC and HM in the federal workplace drug-testing programs. This study characterized the disposition of HC in human urine. Twelve healthy, drug-free, adults were administered a single, oral 20 mg immediate-release dose of HC in a controlled clinical setting. Urine specimens were collected at timed intervals for up to 52 h and analyzed by LC-MS-MS (limit of quantitation 5 50 ng/mL) with and without enzymatic hydrolysis. All specimens were also analyzed for creatinine and specific gravity (SG). HC and norhydrocodone (NHC) appeared within 2 h followed by HM and DHC. Peak concentrations of HC and metabolites occurred at 3-9 h. Peak hydrolyzed concentrations were in the order: NHC > HC > HM > DHC. Only HM was excreted extensively as a conjugated metabolite. At a cutoff concentration of 50 ng/mL, detection times were ∼28 h for HC, 40 h for NHC, 26 h for HM and 16 h for DHC. Some specimens did not contain HC, but most contained NHC, thereby facilitating interpretation that HC was the administered drug. Creatinine and SG measures were highly correlated. Creatinine corrections of HC urinary data had variable effects of lowering or raising concentrations. These data suggest that drug-testing requirements for HC should include a hydrolysis step and a test for HM.
Introduction
Hydrocodone (HC) is a semi-synthetic opioid that is orally active as an antitussive and an analgesic medication for the treatment of moderate to moderately severe pain. At high doses or in sensitive patients, HC may produce dose-related respiratory depression by acting directly on the brain stem respiratory center. Like all narcotics, HC may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a vehicle or operating machinery. Presently, HC is only available in the USA in prescription form in combination with noncontrolled active ingredients such as acetaminophen, non-steroidal antiinflammatory drugs (NSAIDs), antihistamine, expectorant or homatropine (Schedule III; Control Substance Act), although there is interest in the pharmaceutical industry in developing a single-entity product. The combination product, HC with acetaminophen, is the most frequently prescribed opioid drug in the USA with .136 million prescriptions dispensed in 2011 (1) .
The purpose of combining HC with noncontrolled drugs such as acetaminophen is primarily 2-fold: (i) enhancement of analgesia and (ii) restriction of the intake of HC because of the side effects and toxicity of higher-than-prescribed doses of the noncontrolled drug. It is well known that acetaminophen overdose is the leading cause of acute liver failure in the developed world (2) . Alcohol use, especially when used chronically, augments the toxic potential of acetaminophen. Since HC is generally abused orally, often in combination with alcohol, there is concern among drug abusers about the toxic effects of acetaminophen; concern that is often expressed on the Internet websites that support recreational drug use. The desirability of HC as a drug of abuse combined with concerns about acetaminophen toxicity led to the development of a means of separating HC from acetaminophen. The 'Cold Water Extraction' method is frequently discussed on the Internet as a household-based chemical method for removing acetaminophen from HC and other combination products (3) . The method relies on separating the highly watersoluble opiate salt (e.g., HC bitartrate) from the poorly watersoluble acetaminophen by filtration. It is then recommended that the filtered solution containing the purified opiate be consumed orally. Other less soluble components, e.g., aspirin and ibuprofen, are also claimed to be removed by this method.
As a result of its psychoactive properties, availability and development of tampering procedures for separation from acetaminophen, HC has become one of the most commonly misused prescription drugs in the USA. Of particular concern is the prevalence of illicit use of HC among adolescents. The 2011 Monitoring the Future Survey reported that 2.1, 5.9 and 8.1% of 8th, 10th and 12th graders, respectively, used Vicodin w (combination of HC and acetaminophen) nonmedically in the previous year (4) . In addition, HC was second only to oxycodone in being the most frequently encountered opioid pharmaceutical (40,030 items) in drug evidence submitted to state and local forensic laboratories as reported in 2011 by the National Forensic Laboratory Information System (5) .
Although HC is effective orally, its absolute bioavailability does not appear to be known. HC is metabolized by O-demethylation via liver enzymes (CYP2D6) to hydromorphone (HM) (6) and by N-demethylation (CYP3A4) to norhydrocodone (NHC) (7) . The enzyme CYP2D6 is inactive (poor metabolizers, PMs) in 7% of the Caucasian population; the frequency of PMs appears to be somewhat higher in Black Americans (8) . In addition to these oxidative metabolic pathways, there is a 6-keto-reductase pathway that converts the 6-keto-group of HC and HM to epimeric alcohols (9) . The 6-a-hydrocodol metabolite of HC is more commonly known as dihydrocodeine (DHC) and is also marketed commercially as a semi-synthetic opioid analgesic. Figure 1 illustrates the key metabolic pathways for HC. The analgesic potency of these drugs follows the general order: HM . HC . DHC (9) . The interpretation of test results involving HC, HM and DHC can be difficult at times, because HM and DHC may be present either as metabolites of HC or be administered from a commercial source.
This study is part of an ongoing series of research studies designed to characterize the time course of excretion of semisynthetic opioids in various bodily fluids. The focus of the current research was to document individual patterns of excretion of HC and its metabolites in urine. Twelve human subjects were dosed under controlled conditions with a single 20-mg dose of HC bitartrate. All specimens were analyzed by LC-MS-MS for total (with enzymatic hydrolysis) and free (without hydrolysis) drug and metabolites. Creatinine and specific gravity (SG) measures were also taken for all specimens.
Experimental

Subjects and specimens
This was a single-center, clinic-based (SNBL Clinical Pharmacology Center, Baltimore, MD, USA), single-dose study with 12 subjects who were orally administered two tablets of Norco w 10/325 together with 240 mL of room temperature water. Each Norco tablet contained 10 mg of HC bitartrate and 325 mg of acetaminophen. Thus, an equivalent of 20 mg of HC bitartrate (12.1 mg HC free base) and 650 mg of acetaminophen was administered to each subject. Urine specimens were collected on 3 separate days following drug administration on Day 1. The study was conducted in an unblinded fashion and was not placebo controlled. All subjects were healthy adult volunteers who met the inclusion/exclusion criteria, provided informed consent and had not used opioids in the last 3 months or food products containing poppy seeds within the last week. The study was approved by an Institutional Review Board. Seven males (M) and five females (F) participated in the study. Their mean age (range) was 33.9 (24-44) years and mean weight (range) was 76.8 (49.0-100.0) kg. The subjects identified themselves as follows: 10, Black or African American; 1, White and 1, Multiracial. Following medical and toxicology screening of urine for drugs of abuse, subjects were confined at the clinic beginning the day prior to dosing until at least 36 h post-dose. Subjects returned to the clinic on Day 3 for a period of 48-52 h. Urine specimens were collected prior to dosing (baseline) and as pooled collections thereafter. Pooled urine collections for each of the 12 individuals were obtained at the following times (h) after dosing: 0-2; 2-4; 4-6; 6-8; 8-10; 10-12; 12-14; 14-24; 24-28; 28-32; 32-36 and 48-52. Subjects were allowed to leave the clinic between the interval of 36-48 h, and no urine was collected during that time. Specimen volumes were measured and two aliquots (30 mL each) were transferred to polypropylene bottles and frozen until time of analyses. Other biological specimens (oral fluid and blood) were also collected in this study and will be the subject of future publications.
LC-MS-MS analyses
All urine specimens were analyzed by Aegis Sciences Corporation (Nashville, TN, USA) by a validated LC-MS-MS method for 10 opioid analytes (HC, HM, NHC, DHC, oxycodone, oxymorphone, noroxycodone, codeine, morphine and norcodeine) (10) . For this study, two additional analytes (noroxymorphone and normorphine) were validated and incorporated into the assay. The precursor and product ions for noroxymorphone were 288 . 213 and 288 . 184 and for normorphine, 272 . 152 and 272 . 165. Urine specimens were analyzed for free analyte and for total analyte following hydrolysis with b-glucuronidase [Type L-II, Patella vulgate (keyhole limpet), Sigma-Aldrich, St Louis, USA] at pH 5.0 and incubated for 2 h at 608C.
The limit of quantitation (LOQ) for all analytes was 50 ng/mL. LOQ was determined by serial dilution of a fortified urine sample. The criteria for setting the LOQ included (1) a response for LOQ of .10Â signal/noise; (2) a response that meets all the qualitative criteria and (3) a quantitation of within +20% of the target concentration. The upper limit of quantitation (ULOQ) was !4,800 ng/mL for all analytes. The ULOQ had to meet all qualitative criteria and be within +20% of the target concentration. When a specimen exceeded the ULOQ, it was diluted and reanalyzed.
The percent deviation from the weighed-in target concentration and interrun imprecision percent coefficient of variation (%CV) of control samples prepared in urine containing low (200 ng/mL) and high (3,000 ng/mL) of each analyte ranged as follows: low control (n ¼ 10), hydrolyzed, % deviation (211.6-12.0%), interrun imprecision (5.1-9.2%); high control (n ¼ 10), hydrolyzed, % deviation (224.1-9.0%), interrun imprecision (4.6-7.9%); low control (n ¼ 8), unhydrolyzed, % deviation (210.9-0.0%), interrun imprecision (3.2-9.7%) and high control (n ¼ 9; n ¼ 8 for DHC), unhydrolyzed, % deviation (231.9-24.1%), interrun imprecision (3.0-6.9%).
General criteria for the identification and measurement of the analytes were as follows: relative retention time (RRT) of each analyte in the specimen had to be within +0.01 of the calibrator RRT or the retention time of each analyte in the sample had to be within +3% of its respective calibrator RT; ion ratios for the product ions derived from analytes and internal standards in controls and donor specimens had to be within the +20% mean range of those obtained from the corresponding calibrator substances; control samples had to measure within +20% of the in-house determined mean value and negative controls must not have analytes above the LOQ. All quantitative data for drugs and metabolites that met the identification and quantitation (!LOQ) criteria were included in this report. Creatinine and specific gravity SG measurements of urine specimens were performed with a Rudolph Research Analytical J57 Automatic Refractometer (Flanders, NJ, USA). Calibration was checked daily with distilled water and four controls (Scitek) were run with each batch of specimens. All SG data were recorded to four decimal places. Urinary creatinine measurement of specimens was performed with DRI w Creatinine-Detect Test w reagents (Microgenics Corp., Fremont, CA, USA) on an Olympus AU5421 automated analyzer (Beckman Coulter, Brea, CA, USA). A two-point calibration (2 and 20 mg/dL, DRI) was performed daily and two controls (Axion Diagnostics) were run with each batch of specimens.
Results
Subject-reported drug effects
Six (2M/4F) of the 12 subjects reported mild-to-moderate adverse effects (AEs) following administration of HC. There were no serious AEs. The most commonly reported symptoms were nausea (n ¼ 6), lightheadedness (n ¼ 4) and vomiting (n ¼ 3, elapsed time from dosing ranged from 0.9 to 2.3 h). There was one individual report of 'itching'. No subject reported feeling high from the medication.
During the study, subjects provided sufficient urine specimens for the 144 planned urine pool collection periods postdosing with the exception of two male subjects. Subject 4 could not produce a specimen for the 0 -2 or 12-14 h planned collection periods, and Subject 8 could not produce a specimen for the 6 -8 h planned specimen collection. These are denoted as no specimen (NS) in Table I . Of the 141 pooled urine specimens successfully collected, it was noted that 73 (52%) planned pooled specimens represented a single void during the collection interval.
Individual urinary patterns of metabolism and excretion of HC All specimens collected during the baseline period immediately prior to HC dosing tested negative (,LOQ) by LC-MS-MS for the 12 opioid analytes. In addition, all subjects tested negative throughout the study for oxycodone, oxymorphone, noroxycodone, noroxymorphone, codeine, morphine, norcodeine and normorphine with the exception of two specimens. The specimens labeled as collected from Subject 13 for the 0-2 and 2-4 h pool contained only oxycodone and related metabolites. Since there was an ongoing study of oxycodone on the same day in the clinic when these specimens were collected, it was concluded that these specimens were mislabeled. The two specimens are listed in Table I as a missing (M) specimen. A complete listing of concentrations for all other specimens is summarized in Table I for total (hydrolyzed) and free HC, HM, NHC and DHC, and includes measures for specimen volume, creatinine and SG.
Following HC dosing, there was detectable total and free HC in 9 of the 12 subjects during the first collection period (0 -2 h). Of the remaining 3 subject's specimens for that period, Subject 4 did not produce a specimen, Subject 9 was negative for HC, but positive for NHC and Subject 13 specimen was missing. The initial appearances of HC in urine were frequently accompanied by detectable total and free NHC in the same specimen. NHC was generally the most abundant metabolite and was frequently present in higher concentration than HC. Concentrations of total HM and DHC generally became detectable in the 2-4 h collection period. Concentrations of HC and metabolites peaked usually within 3 -9 h and declined thereafter. Figure 2 depicts the mean time course relationships for HC and metabolites (n ¼ 12, hydrolyzed). Figure 3 depicts the variability in excretion of HC in urine by the 12 subjects. Peak concentrations of HC and metabolites (C max ) and time-to-maximum concentrations (T max ) are summarized in Table II together with the percent dose excreted over 36 h. The calculation of percent dose excretion of metabolites was made on a molar basis to account for their change in molecular weight relative to HC. Generally, concentrations of free HC were similar to hydrolyzed HC determinations. Likewise, total and free concentrations of NHC and DHC were similar. In contrast, measures of HM after hydrolysis were greater than those of free HM.
Drug and metabolite combinations and ratios
At a cutoff concentration of 50 ng/mL combined with hydrolysis, HC was most frequently present in combination with HM, NHC and DHC (n ¼ 44, 34.6%). Other combinations of HC were with NHC (n ¼ 26, 20.5%) and combined with HM and NHC (n ¼ 23, 18.1%) and combined with NHC and DHC (n ¼ 7, 5.5%). No positive results were observed for HC in the absence of other metabolites. HC was not detected (!LOQ) in some specimens. The most frequent occurrences of metabolites (in the absence of HC) was NHC alone (n ¼ 18, 14.2%), HM combined with NHC (n ¼ 8, 6.3%) and HM alone (n ¼ 1, 0.8%). Thus, 100 (71.9%) of the 139 specimens collected post-HC administration were positive for HC at a 50-ng/mL cutoff concentration. The percentage of specimens positive for HC in hydrolyzed urine at higher cutoff concentrations was as follows: 100 ng/mL, 59.0%; 150 ng/mL, 53.2%; 300 ng/mL, 38.1%; 500 ng/mL, 26.6%; 1,000 ng/mL, 10.8% and 2,000 ng/mL, 6.5%.
At a cutoff concentration of 50 ng/mL without hydrolysis, HC was most frequently present in combination with NHC (n ¼ 55, 43.7%), with NHC and DHC (n ¼ 30, 23.8%) as well as with HM, NHC and DHC (n ¼ 12, 9.5%). There were 29 (23.0%) specimens in which only NHC was detected.
Ratios of HC to metabolite and metabolite to metabolite were evaluated to determine how they might vary over time following oral ingestion of HC. As shown in Figure 4 , ratios of HC to metabolites generally declined over time, whereas the ratio of HM to DHC remained elevated; however, DHC was not consistently present in all subjects' specimens and its presence was of shorter duration than HC and other metabolites.
Creatinine, specific gravity and creatinine corrections Creatinine and SG measures taken following HC administration were highly correlated (R 2 ¼ 0.890, n ¼ 139). Baseline (predose) measures (range) of creatinine and SG averaged 53.9 (18.1-100.8) and 1.0066 (1.0025-1.0123) mg/dL, respectively. During the first collection period (0-2 h) following drug administration, creatinine and SG averaged 27.9 (10.1-39.2) and 1.0037 (1.0017-1.0056) mg/dL, respectively. During the second collection period (2-4 h), creatinine and SG averaged 107.4 (12.1-238.4) and 1.0111 (1.0023-1.0281) mg/dL, respectively. During the ensuing time after drug administration, creatinine and SG were similar to baseline measures. Creatinine correction of HC concentrations was conducted using a 'standard reference creatinine concentration of 100 mg/ dL' (11) . Creatinine corrections of HC urinary data had variable effects of lowering or raising concentrations. The effects of creatinine correction on HC are illustrated in Figure 5 for the two subjects who were selected on the basis of having the highest baseline creatinine concentration (Subject 6, Panel A) and the lowest baseline creatinine concentration (Subject 21, Panel B).
Detection times
Mean detection times (time to last detectable positive) for HC, HM, NHC and DHC in hydrolyzed and nonhydrolyzed urine specimens are presented in Table III across a range of cutoff concentrations. All detection times were measured based on the time from drug administration to the end of the specimen collection period of the last positive specimen. Cutoff concentrations chosen for evaluation encompassed a range from the lowest (50 ng/mL, LC-MS-MS assay LOQ for HC, HM, NHC and DHC) to the highest (2,000 ng/mL, Department of Health and Human Services (DHHS) cutoff concentration for morphine and codeine (12)). Generally, HC detection times were longer than that for HM, shorter than that for NHC and considerably longer than that for DHC. Detection times for HC, NHC and DHC in urine specimens without hydrolysis (free drug) were similar to those determined after hydrolysis, whereas that of HM without hydrolysis was considerably shorter than that observed with hydrolyzed specimens.
Discussion
Currently, semi-synthetic opioids are being tested in private sector workplace programs, and there is interest in their inclusion in the federal workplace drug-testing programs. Their widespread abuse has become a major public health concern. According to the Quest Diagnostics Drug Testing Index TM , 'Hydrocodone and oxycodones remain the most detected prescription opiates in the US general workforce, with 1.3 and 1.1% positivity rates, respectively, in the first half of 2011' (13) . Accordingly, this study was undertaken specifically to enhance the existing scientific knowledge base and literature regarding the disposition of HC and metabolites in human biological specimens. This initial report details the time course of HC and metabolites in human urine following administration of a single controlled dose of 20 mg of HC bitartrate.
The major metabolites of HC have been delineated in animal (9) and human (7, 9, 14, 15) studies as HM, NHC and DHC. The most detailed previous report of HC and metabolite excretion in urine appears to be the study by Valtier and Bebarta (14) . In that study, seven subjects were administered a single, 10 mg dose of HC. HC, HM and NHC were measured in hydrolyzed urine by LC-MS-MS. Consistent with the current results, HM was detected generally at lower concentrations than HC and NHC and for a shorter detection time than NHC. NHC was detected at higher concentrations than HC and for a longer period of time. In some cases, NHC was present in the absence of HC. Earlier, Cone et al. (16) reported that NHC was detected in the absence of HC in 7.8% of urine specimens (n ¼ 59) from pain patients who were being treated with HC. Further, 59.3% of those specimens contained NHC in the absence of other HC metabolites. In the current study, HC generally appeared in hydrolyzed urine in the first collection period (0-2 h) and was accompanied by NHC in similar concentrations. Thereafter, NHC frequently exceeded HC concentrations. Although HM has a half-life (1.7 -3.9 h) (17) similar to that of HC (2.5-4.0 h) (18), HM was detectable longer than HC in five subjects. As noted, HM was present in nine specimens in the absence of HC (50 ng/mL cutoff concentrations, hydrolyzed). Eight of those specimens also contained NHC in concentrations of .50 ng/mL. Based on the prevalence, higher concentration and longer detection time of NHC relative to HC, it is clear that testing for NHC would serve as a valuable biomarker of HC use.
Comparisons of results from hydrolyzed urine specimens with those from nonhydrolyzed specimens indicated that HC, NHC and DHC were excreted as free, nonconjugated drug/metabolite, whereas HM was excreted primarily in the conjugated form (Table III) . Direct administration of HM to human subjects (4 mg via oral route) has also been reported to result in the urinary excretion primarily of conjugated HM (19) .
High variability was observed in the excretion of HC (Figure 3 ) and metabolites. There are numerous factors that may contribute to such variability. Because 3 of the 12 subjects vomited following drug administration, it is possible that some drug was lost in the process. The shortest elapsed time after dosing before vomiting occurred was 54 min. Comparison of the mean total percent drug and metabolite (16.4%) excreted in urine by the three individuals (Subjects 17, 20 and 23) with those of the other 9 individuals (36.0%) suggest that vomiting might have caused some drug loss; however, comparison of maximum HC and metabolite concentrations and their respective detection times for the three subjects with those of the remainder of the subjects did not support this conclusion. Other factors that could have contributed to individual variability in this study include the amount of fluid intake and individual rates of absorption, metabolism and excretion. The amount of fluid intake has been shown to greatly influence urine cocaine and marijuana metabolite concentrations (20) . Baseline creatinine measures of the 12 subjects in the current study were highly variable and ranged from 18.1 to 100.8 mg/dL. There is also potential variability in individual metabolic processes. For HC, there are the competing influences by the primary oxidative enzyme systems (CYP3A4 and CYP2D6) that demethylate HC to NHC and HM, respectively. The activity of the CYP3A4 enzyme can be inhibited by numerous drugs and is also subject to induction (7, 21) . Genetic polymorphisms of the CYP2D6 enzyme lead to large interindividual differences in the formation and disposition of metabolites of HC. Individuals who have limited CYP2D6 activity are known as PMs. These individuals produce and excrete very little O-demethylated metabolites in urine. The remainder of the population has highly variable CYP2D6 activity and may be characterized as intermediate, extensive and ultra-rapid metabolizers. The incidence of CYP2D6 PMs in white populations is 6-10%; in the Black American population, the frequency of PMs appears to be somewhat higher (8) . Interestingly, in the current study, one individual (Subject 4, Table I ) appears to be a CYP2D6 PM, although this was not confirmed by further testing. Two additional subjects (Subjects 16 and 22) produced specimens that tested positive for HM only at very low concentrations.
Study limitations
The current study involved administration of a single dose of HC bitartrate as an immediate-release formulation to 12 individual, drug-free, nonopioid tolerant, healthy individuals. Although the three major metabolites of HC (HM, NHC and DHC) were measured in this study, minor metabolites (e.g., b-hydrocodol, norhydromorphone) were not included. Also, only one HC dose was administered in this study and other types of HC formulations were not explored. In the near future, it is likely that controlled release formulations of HC will be commercially developed as prescription medications. Presumably, such formulations will exhibit somewhat longer detection times for parent drug and metabolites than did the immediate-release formulation used in this study. The detection times measured in this study for some analytes may also be somewhat underestimated because of the study design that allowed discharge of subjects between 36 and 48 h with NS collections performed during that time. In addition, the present study examined HC to metabolite ratios, but lacked equivalent information for HM when HM is administered as a separate pharmaceutical product rather than being present as a metabolite of HC. Acquisition of such data requires additional clinical studies to be completed before these data become available.
Conclusions
This study describes the metabolism and disposition of HC and three primary metabolites (NHC, HM and DHC) in urine following oral administration of 20 mg of immediate-release HC bitartrate to 12 healthy, drug-free subjects. HC and NHC were initially detected in the majority of subject's specimens within 2 h of drug administration. HC was most frequently detected in combination with NHC. In some cases, HC disappeared from urine before NHC and HM. Consequently, some specimens contained only metabolites late in the excretion phase (!24 h post-dosing). NHC was frequently present and its detection would lead to the interpretation that HC was the administered drug; however, there was 1 specimen that contained only HM at relatively low concentrations (!50 ng/mL cutoff concentration). Consequently, this result would be consistent with either HC or HM use. Comparison of hydrolyzed versus nonhydrolyzed results indicated that HC, NHC and DHC were excreted nearly completely in the unconjugated form, and HM was excreted primarily in the conjugated form. Consequently, the hydrolysis step is necessary for HM detection. Considerable variability was apparent in the excretion of HC and metabolites of the 12 subjects. Some variability could be reduced by creatinine or SG corrections; however, there was also evidence of considerable enzyme variability. One of the 12 subjects appeared to be a CYP2D6 PM who did not produce detectable amounts of HM from HC. Detections times for HC and metabolites were ,5 h at a 2,000 ng/mL cutoff concentration. The use of the 50 ng/mL as the cutoff concentration extended detection times for HC to 28 h. Inclusion of NHC further increased the detection time to 40 h. Overall, these data suggest that drug-testing requirements for HC should include tests for HC and HM in hydrolyzed urine. In addition, some consideration should also be given to allowing testing for NHC as a means of distinguishing HC from HM use. Two subjects were positive for NHC at a cutoff concentration of !100 ng/mL in the 48-52 h collection; one subject was positive for NHC at a cutoff concentration of !50 ng/mL in the 48 -52 h collection and one subject was positive for NHC and HM at a cutoff concentration of !50 ng/mL in the 48 -52 h collection.
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